The common side effects of oxymetholone include depression , lethargy , headache , swelling , rapid weight gain , priapism , changes in skin color, urination problems, nausea , vomiting , stomach pain (if taken on an empty stomach), loss of appetite , jaundice , breast swelling in men, feeling restless or excited, insomnia , and diarrhea .  In women, side effects also include acne , changes in menstrual periods , voice deepening , hair growth on the chin or chest , pattern hair loss , enlarged clitoris , and changes in sex drive .   Because of its 17α-alkylated structure, oxymetholone is hepatotoxic .  Long term use of the drug can cause a variety of serious ailments, including hepatitis , liver cancer , and cirrhosis ; therefore periodic liver function tests are recommended for those taking oxymetholone. 
Results from randomized controlled trials in patients with first acute renal allograft rejection episodes refractory to conventional steroid therapy have demonstrated that ATGAM, when administered in conjunction with standard therapy, yields efficacy results superior to those of standard therapy alone. One study investigated two different regimens of ATGAM; immediate and delayed therapy. Patients were enrolled at the time of first rejection episode and randomized among three treatment groups: control (no ATGAM), immediate ATGAM, and delayed ATGAM. Patients in all three treatment groups received standard rejection therapy in the form of bolus doses of Solu-Medrol®15 mg/kg/day IV, while patients in the two ATGAM groups received ATGAM therapy in addition to Solu-Medrol®. In the immediate ATGAM group, ATGAM administration started at the time of diagnosis of rejection (concurrent with standard therapy). In the delayed ATGAM group, ATGAM administration started on rejection day 4 (following the first three doses of Solu-Medrol®). Patients in both of the treated groups received from 10 to 21 doses of ATGAM. Results favored the two ATGAM groups (and particularly the immediate ATGAM group) in both outcome of first rejection and functional graft survival. The improvement in functional graft survival was statistically significant (p=). There was also a statistically significant difference in patient survival rate favoring the ATGAM-treated groups (p=).
Anapolon 50mg contains 17-alpha alkylated which is a liver toxic compound. This side effect can be avoided with a strict dietary regime and using a liver protectant supplement. Anapolon 50mg can produce the following side effects: nausea, vomiting, stomach aches, decrease appetite, headaches, insomnia, and diarrhea. Other side effects are oily skin, acne, body and facial hair growth; it may cause problems in persons with predisposition to baldness. Anapolon can also produce several mood side effects like anxiety or nervousness. Generally, most of these effects are considered to be minor as they tend to subside as the body adapts to the medication.